Prima BioMed (NASDAQ:IMMP) Share Price Passes Above Fifty Day Moving Average – Should You Sell?

Prima BioMed Ltd (NASDAQ:IMMP) shares crossed above its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of $0.40 and traded as high as $0.4104. Prima BioMed shares last traded at $0.3922, with a volume of 153,277 shares.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the stock. Maxim Group raised shares of Prima BioMed from a “hold” rating to a “buy” rating in a research note on Wednesday, June 17th. Wall Street Zen raised shares of Prima BioMed to a “hold” rating in a research report on Saturday, April 18th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Prima BioMed in a report on Friday, July 10th. One analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $5.50.

Prima BioMed Price Performance

The company has a 50 day moving average price of $0.40 and a 200 day moving average price of $1.09.

Institutional Trading of Prima BioMed

An institutional investor recently raised its stake in Prima BioMed stock. Jane Street Group LLC boosted its holdings in shares of Prima BioMed Ltd (NASDAQ:IMMP) by 14.7% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 51,574 shares of the biotechnology company’s stock after buying an additional 6,617 shares during the period. Jane Street Group LLC’s holdings in Prima BioMed were worth $91,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 2.32% of the company’s stock.

Prima BioMed Company Profile

Prima BioMed, trading as IMMP on NASDAQ, is a clinical-stage biotechnology company specializing in the development of immunotherapy products for cancer treatment. The company’s core technology platform centers on targeting the lymphocyte activation gene-3 (LAG-3), a checkpoint receptor that modulates T-cell activity. Prima BioMed’s lead candidate, eftilagimod alpha (IMP321), is a soluble LAG-3 protein designed to enhance antigen-presenting cell function and stimulate a tumor-specific immune response.